Tavaborole

Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Tavaborole began phase III clinical trials in December 2010[1] and was approved by the US FDA in July 2014.[2] The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death, eliminating the fungal infection.

Tavaborole
Clinical data
Trade namesKerydin
Other namesAN2690
Routes of
administration		Topical
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.218.130
Chemical and physical data
FormulaC7H6BFO2
Molar mass151.93 g·mol−1
3D model (JSmol)

Medical uses

Tavaborole is used in the treatment of onychomycosis. In clinical trials, tavaborole was more effective than the vehicle (ethyl acetate and propylene glycol) alone in curing onychomycosis. In two studies, fungal infection was eliminated using tavaborole in 6.5% of the cases vs. 0.5% using the vehicle alone, and 27.5% vs. 14.6% using the vehicle alone.[3]

Side effects

Application site exfoliation, erythema (rash), and irritation are possible side effects, and may occur in less than 5% of individuals.[3]

Pharmacology

Pharmacokinetics

Tavaborole, when prepared with a 1:1 mixture of ethyl acetate and propylene glycol, has the ability to fully penetrate through the human nail. In studies with cadaver fingernails, a 5% solution of tavaborole penetrated the nail an average of 524.7 mcg/cm2 after two weeks of daily use.[3]

Tavaborole is detectable in the blood at a level of 3.54 ng/mL after a single use of 0.2 mL of the 5% solution. Tavaborole has an elimination half-life of 28.5 hours, a maximum concentration of 5.17 ng/mL after two weeks of daily use, and takes 8 days to reach the maximum concentration.[3]

Society and culture

Commercial

Originally developed by Anacor, it is now marketed in the United States by Novartis subsidiary Sandoz. Anacor was paid US$65 million and also entered into a profit sharing scheme for future sales.[4] A 10 mL bottle of a 5% solution of tavaborole will cost the patient without insurance about $1,356.[5]

gollark: People talk about gender bias in tech quite a lot, and weirdly enough my computer science class next year of 11ish people is entirely male.
gollark: I'm sure if you have free healthcare, *it* could never be overloaded or anything.
gollark: There's 9axes, too, which... has 9 axes... so that would be a political... 9-cube.
gollark: Well, 8values has 4 axes, so you could map it onto a political tesseract.
gollark: There's a better one with a conservative/progressive axis too, but I don't have the link.

See also

Crisaborole – a structurally related topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema)

References
  1. Clinical trial number NCT01270971 for "Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail" at ClinicalTrials.gov
  2. "FDA Approves Anacor Pharmaceuticals' KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails". Market Watch. July 8, 2014.
  3. Elewski BE, Aly R, Baldwin SL, González Soto RF, Rich P, Weisfeld M, et al. (July 2015). "Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies". Journal of the American Academy of Dermatology. 73 (1): 62–9. doi:10.1016/j.jaad.2015.04.010. PMID 25956661.
  4. "Anacor's Kerydin to Be Commercialized by Sandoz in the U.S." Zacks.com. 22 July 2014. Retrieved 7 October 2015.
  5. "KERYDIN". Retrieved 12 August 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.